Marcelo Marotti
Summit (United Kingdom)(GB)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Sarcoma Diagnosis and Treatment, Gastric Cancer Management and Outcomes, Gastrointestinal Tumor Research and Treatment
Most-Cited Works
- → Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer(2017)5,100 cited
- → Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer(2016)3,266 cited
- Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer(2017)
- → A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors(2010)106 cited
- → ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection(2018)106 cited
- → A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer(2020)71 cited
- → Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma(2014)67 cited
- → Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma(2009)56 cited
- → Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases(2008)44 cited
- → The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL‐C Value – an Evaluation of Rosuvastatin therapY compared with atorvastatin(2005)32 cited